اللهم صل وسلم على سيدنا وحبيبنا وشفيعنا محمد وعلى آله وصحبه أجمعين ..
ومن يتق الله يجعل له مخرجاَ .. ويرزقه من حيث لا يحتسب ..
احفظ الله يحفظك .. احفظ الله تجده تجاهك ..
واجعلوا لنا نصيباَ من دعائكم .. 

This video discusses two major types of acute leukemia - acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL). Also included are the major subtypes of AML and ALL as well symptoms resulting from these cancers.

Histopathology Blood --Acute leukemia

This educational webinar will give an overview of how ALL is treated today and the significance of ’hot topics’ and key treatment development advances published and discussed at 2022 international hematology conferences.

What is new and what does this mean for patients?

We will be joined by:

Dr Tobias Menne Consultant Haematologist, Clinical Director for Research, Honorary Senior Lecturer Newcastle University (UK)

Anne - Pierre Pickaert Patient Advocate, Acute Leukaemia Advocates Network (France)

This webinar may be useful for people affected by a diagnosis of ALL: patients, family members, supporters and advocates.

Dr Stefan Grupp gives a press conference at ASH 2018 about the ELIANA trial.

He diescribes how tisagenlecleucel continues to show durable remissions in paediatric and young patients with relapsed or treatment-resistant acute lymphocytic leukaemia.

Watch his interview with ecancer here:

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

CGC Webinar Series - June 28, 2022
Presenter: Dr. Zhaohui Gu

B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric cancer. It consists of over 20 subtypes defined by distinct genetic alterations and gene expression profiles (GEPs), which makes accurate classification of B-ALL subtypes still challenging in clinical practice. Currently, we are analyzing the largest B-ALL cohort around the world to identify multi-omics signatures of each B-ALL subtype and aim to develop a robust B-ALL classification system based on bulk and single-cell RNA-seq. Our goal is to translate the advances in genomics research of B-ALL to precision clinical diagnosis and eventually improve the treatment strategies and outcomes for patients.

Dr. Zhaohui Gu is an assistant professor in the Department of Computational and Quantitative Medicine & Systems Biology at Beckman Research Institute of City of Hope.

Dr. Gu earned his Ph.D. degree in Bioinformatics and Cancer Biology at Shanghai Jiao Tong University. Then he did his postdoctoral training at St. Jude Children‘s Research Hospital. Dr. Gu‘s research has been recognized and supported by the American Society of Hematology (ASH) Scholar Award, The Leukemia & Lymphoma Society (LLS) Special Fellow Award, and NIH/NCI Pathway to Independence Award (K99/R00).

Dr. Gu‘s research examines the genetic basis of high-risk acute leukemia that are of unknown etiology. His work has capitalized upon a long-standing study of the genomics of acute lymphoblastic leukemia (ALL), the most common childhood cancer, that has resulted in multiple publications and influenced the understanding of the genetic basis of ALL. Specifically, his recent project using transcriptome sequencing and innovative computational pipelines has refined ALL classification into over 20 distinct subtypes and resulted in major advances in diagnostic and therapeutic approaches in ALL.

Press brief by Max Topp, MD of the University of Würzburg, Würzburg, Germany, at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.